Rating Change
Needham analysts initiated coverage on CAMP4 Therapeutics Corporation (NASDAQ:CAMP) with a rating of Buy on October 15, 2026.
new coverageNASDAQ:CAMP
Needham Initiates Coverage on CAMP4 Therapeutics Corporation (CAMP) with Buy
Needham analysts initiated coverage on CAMP4 Therapeutics Corporation (NASDAQ:CAMP) with a rating of Buy on October 15, 2026.
At publication ·
What changed
CAMP4 Therapeutics Corporation (NASDAQ:CAMP) · new coverage
- Firm
- Needham
- Rating
- Buy
- Price at event
- $3.48
- Market capitalization
- $125.7M
At a glance
Key takeaways
- Needham initiated Buy coverage on CAMP4 Therapeutics (NASDAQ:CAMP) on October 15, 2026, with the stock trading at $3.48 and a market cap of $125.7M.
Market Context
CAMP4 Therapeutics Corporation operates in the Healthcare sector. The stock currently trades at $3.48 with a market capitalization of $125.7M.
Analyst coverage from Needham provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CAMP4 Therapeutics Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for CAMP4 Therapeutics Corporation
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 15, 2026 | Needham | Buy | N/A |
| Oct 05, 2026 | Oppenheimer | Outperform | N/A |
| Sep 29, 2026 | Chardan Capital | Buy | N/A |
| Aug 14, 2026 | Piper Sandler | Overweight | N/A |
| Jun 16, 2026 | JP Morgan | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View CAMP Stock Page
Frequently Asked Questions
What does the Buy rating mean for CAMP?
A rating of Buy from Needham reflects the analyst's outlook on CAMP4 Therapeutics Corporation (NASDAQ:CAMP). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CAMP forecast page.